NCT06821490View on ClinicalTrials.gov

Validation of TAD in HER-2 with More Than 2 Lymph Nodes

Enrolling by invitationOBSERVATIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

February 28, 2026

Conditions
Breast Carcinoma Metastatic in Lymph NodeHER2 Positive Breast Carcinoma
Interventions
PROCEDURE

Targeted axillary dissection and subsequently a lymphadenectomy

Selective sentinel lymph node biopsy is performed, along with biopsy of the node marked at diagnosis. Subsequently, a lymphadenectomy is performed, with the three samples separated for pathological study during the same surgical procedure

Trial Locations (1)

46010

Hospital Clínico de la Comunidad Valenciana, Valencia

All Listed Sponsors
lead

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER